Literature DB >> 7872243

Bu ji (hozai) for treatment of postoperative gastric cancer patients.

Y Horie1, K Kato, S Kameoka, K Hamano.   

Abstract

We proposed that postgastrectomy cancer patients with organ deficit were xu zheng, or of deficient constitution, and administered bu ji or supplementary regimen to them. With alleviation of the symptoms, our diagnosis seemed correct from the traditional medicine perspective. Interleukin 2 reactivity, natural killer activity, nutritional index and bone mineral indices also improved. Such results suggest that our diagnosis was also correct according to Western medical theory. In addition, nutrition seemed to have positive relationship with NK activity and bone mineral content. Therefore, administration of bu ji seemed useful to improve the quality of life of postoperative cancer patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7872243     DOI: 10.1142/S0192415X94000371

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  5 in total

1.  Giant Krukenberg tumor from a perforated gastric cancer that was successfully removed after multidisciplinary therapy: report of a case.

Authors:  Masaki Sunagawa; Masatoshi Isogai; Tohru Harada; Yuji Kaneoka; Keitaro Kamei; Atsuyuki Maeda; Yuichi Takayama
Journal:  Surg Today       Date:  2012-09-18       Impact factor: 2.549

2.  Japanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8+ T cells.

Authors:  Shun Takaku; Masumi Shimizu; Hidemi Takahashi
Journal:  Oncol Lett       Date:  2017-03-28       Impact factor: 2.967

3.  Japanese Kampo Medicine Juzentaihoto Improves Antiviral Cellular Immunity in Tumour-Bearing Hosts.

Authors:  Shun Takaku; Masumi Shimizu; Rimpei Morita
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-13       Impact factor: 2.650

Review 4.  The translational aspect of complementary and alternative medicine for cancer with particular emphasis on Kampo.

Authors:  Marie Amitani; Haruka Amitani; Robert A Sloan; Hajime Suzuki; Nanami Sameshima; Akihiro Asakawa; Yasuhito Nerome; Tetsuhiro Owaki; Akio Inui; Etsuo Hoshino
Journal:  Front Pharmacol       Date:  2015-08-06       Impact factor: 5.810

5.  Japanese Kampo Medicine Juzentaihoto Enhances Antitumor Immunity in CD1d-/- Mice Lacking NKT Cells.

Authors:  Shun Takaku; Masumi Shimizu; Hidemi Takahashi
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.